Rhythm Biosciences Ltd
Rhythm Biosciences Secures Major Distribution Deal for ColoSTAT with 4Cyte Pathology
Rhythm Biosciences (ASX: RHY) has signed a significant non-exclusive distribution agreement with 4Cyte Pathology for its ColoSTAT test.
Rhythm Biosciences begins ColoSTAT commercial deployment with first physician enrollment
Rhythm Biosciences (ASX: RHY) has initiated the commercial deployment of its ColoSTAT test by enrolling the first physician in its capped Access Program.
Rhythm Biosciences Secures Key Manufacturing Deal for ColoSTAT
Rhythm Biosciences (ASX:RHY) has secured a multi-year manufacturing agreement with Quansys Biosciences for its ColoSTAT reagent kits, ensuring scalab
Rhythm Biosciences’ 2G ColoSTAT colorectal cancer detection kit outperforms predecessor in key testing
Medical diagnostics company Rhythm Biosciences (ASX: RHY) has confirmed that the second version of its ColoSTAT kit for the detection of colorectal cancer has shown significant outperformance on the original. Preliminary testing of 200 patient serum samples using the new multiplex Alpha antibody kit has revealed superior analytical results compared to tests performed on the […]